Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
With further follow-up of MONALEESA-3, Kisqali plus fulvestrant achieved a median overall survival (OS) of more than five-and-a-half years (67.6 months) in the first-line (1L) setting for...
-
Swiss Biotech DayLSX World Congress BioEquity Europe H.C. Wainwright Global Investment ConferencePrecisionMed Expo & Summit Foro MedCap BME MADRID, Spain and CAMBRIDGE, Mass., April 29, 2022 ...
-
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong...
-
Combined company to be renamed Lisata Therapeutics upon transaction closing Combination will create a financially sound Nasdaq-listed company with a diverse product development pipeline, strong...
-
SINGAPORE and SEOUL, South Korea, April 19, 2022 (GLOBE NEWSWIRE) -- AUM Biosciences, a global clinical-stage biotech company, focused on discovering and developing novel targeted oncology...
-
싱가포르/한국 서울, April 19, 2022 (GLOBE NEWSWIRE) -- 임상 단계 바이오테크 기업으로 항암 신약 치료제 발견 및 개발에 중점을 두고 있는 AUM Biosciences는 한국의 혁신 주도 제약 및 헬스케어 회사인 Handok Inc. [002390: KOSPI], CMG Pharmaceutical Co. Ltd....
-
- Company to host call today, April 14, 2022 at 8:00 am ET - Conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or +1-201-389-0879 (International). The passcode is...
-
Vijoice is first approved treatment to specifically address the root cause of PROS conditions in select patients 2 years of age and older1 PROS is a spectrum of rare conditions and is characterized by...
-
Dose-escalation and dose-expansion trial evaluating potential of NGM831, an ILT3 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) initiated and...
-
- 2022 clinical data readouts on track to show potential best-in-class safety profile for anti-CTLA-4 programs (ADG116, ADG126) with PD-1 for proven and new indications, thereby enabling greater...